222 related articles for article (PubMed ID: 26890336)
1. Nano- and micro-based systems for immunotolerance induction in multiple sclerosis.
Pires LR; Marques F; Sousa JC; Cerqueira J; Pinto IM
Hum Vaccin Immunother; 2016 Jul; 12(7):1886-90. PubMed ID: 26890336
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis: Skin-induced antigen-specific immune tolerance.
Wildner P; Selmaj KW
J Neuroimmunol; 2017 Oct; 311():49-58. PubMed ID: 28803660
[TBL] [Abstract][Full Text] [Related]
3. Immune modulating peptides for the treatment and suppression of multiple sclerosis.
Badawi AH; Siahaan TJ
Clin Immunol; 2012 Aug; 144(2):127-38. PubMed ID: 22722227
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic approaches for multiple sclerosis.
De Jager PL; Hafler DA
Annu Rev Med; 2007; 58():417-32. PubMed ID: 17217332
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.
Gharibi T; Ahmadi M; Seyfizadeh N; Jadidi-Niaragh F; Yousefi M
Cell Immunol; 2015 Feb; 293(2):113-21. PubMed ID: 25596473
[TBL] [Abstract][Full Text] [Related]
6. Novel immunomodulatory approaches for the management of multiple sclerosis.
Kantarci OH; Pirko I; Rodriguez M
Clin Pharmacol Ther; 2014 Jan; 95(1):32-44. PubMed ID: 24173041
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
Aktas O; Kieseier B; Hartung HP
Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
[TBL] [Abstract][Full Text] [Related]
8. The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis.
Payne N; Siatskas C; Barnard A; Bernard CC
Curr Stem Cell Res Ther; 2011 Mar; 6(1):50-62. PubMed ID: 20955155
[TBL] [Abstract][Full Text] [Related]
9. [New and emerging treatments for multiple sclerosis].
Louapre C; Maillart É; Papeix C; Lubetzki C
Med Sci (Paris); 2013 Dec; 29(12):1105-10. PubMed ID: 24356140
[TBL] [Abstract][Full Text] [Related]
10. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.
Karussis D; Petrou P
Immunol Res; 2018 Dec; 66(6):642-648. PubMed ID: 30443887
[TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Kasper LH; Shoemaker J
Neurology; 2010 Jan; 74 Suppl 1():S2-8. PubMed ID: 20038759
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific tolerization approaches in multiple sclerosis.
Lutterotti A; Martin R
Expert Opin Investig Drugs; 2014 Jan; 23(1):9-20. PubMed ID: 24151958
[TBL] [Abstract][Full Text] [Related]
13. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein.
de Rosbo NK; Ben-Nun A
J Autoimmun; 1998 Aug; 11(4):287-99. PubMed ID: 9776706
[TBL] [Abstract][Full Text] [Related]
14. Knowns and unknowns in the future of multiple sclerosis treatment.
Stüve O
J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346
[TBL] [Abstract][Full Text] [Related]
15. Immune tolerance to myelin proteins.
Seamons A; Perchellet A; Goverman J
Immunol Res; 2003; 28(3):201-21. PubMed ID: 14713715
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity.
Patas K; Engler JB; Friese MA; Gold SM
J Reprod Immunol; 2013 Mar; 97(1):140-6. PubMed ID: 23432880
[TBL] [Abstract][Full Text] [Related]
18. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H
BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991
[TBL] [Abstract][Full Text] [Related]
20. DNA-based vaccines for multiple sclerosis: current status and future directions.
Fissolo N; Montalban X; Comabella M
Clin Immunol; 2012 Jan; 142(1):76-83. PubMed ID: 21163708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
